FDA has accepted a supplemental New Drug Application for Rubraca (rucaparib) and granted priority review status to the application with a Prescription Drug User Fee Act date of May 15.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
